Psychedelic Medicine
Stock & Pipeline Tracker
Track every publicly listed psychedelic medicine company — pipeline stages, live stock prices, upcoming FDA catalysts, and clinical trial updates. Last updated 2026-02-25.
| Company↕ | Ticker | Price↕ | Chg %↕ | Stage↓ |
|---|---|---|---|---|
| COMPASS Pathways | CMPS | Phase 3 | ||
| Helus Pharma | HELP | Phase 3 | ||
| Definium Therapeutics | DFTX | Phase 3 | ||
| Enveric Biosciences | ENVB | Preclinical | ||
| AtaiBeckley Inc. | ATAI | Phase 2b Complete | ||
| GH Research | GHRS | Phase 2b Complete | ||
| NRx Pharmaceuticals | NRXP | Phase 2b/3 Complete | ||
| Bright Minds Biosciences | DRUG | Phase 2 Complete | ||
| Filament Health | FLHLF | Phase 2 (Investigator-Initiated) | ||
| AdvisorShares Psychedelics ETF | PSIL | ETF | ||
| Horizon Psychedelic Stock Index ETF | PSYK | ETF |
Disclaimer: Pipeline and stock data are for informational purposes only and do not constitute investment advice. Stock prices are delayed and provided by Financial Modeling Prep. Pipeline data compiled from SEC filings, ClinicalTrials.gov, and company press releases; may not reflect the most recent updates. Always consult official filings for current information. Psychedelic Alpha's Drug Development Tracker is a recommended resource for comprehensive industry coverage.
Private & Notable
These organizations are not publicly traded but are significant players in the psychedelic medicine ecosystem.
Lykos Therapeutics / Resilient Pharmaceuticals
PrivateFDA rejected MDMA-assisted therapy (MDMA-AT) for PTSD in August 2024, citing concerns over functional unblinding, trial design, and risk-benefit assessment. Now rebranded as Resilient Pharmaceuticals, the company must complete a third Phase 3 trial before resubmitting an NDA.
Visit website →Delix Therapeutics
PrivateDeveloping 'tabernanthalog' and related non-hallucinogenic analogs of ibogaine and ketamine that preserve neuroplasticity benefits without the psychedelic experience. Series B funded, private. Science pioneered by Dr. Bryan Roth at UNC Chapel Hill.
Visit website →Usona Institute
PrivateNonprofit research organization with FDA Breakthrough Therapy Designation for psilocybin in MDD. PSIL301 Phase 2/3 trial ongoing. All intellectual property will remain non-proprietary and freely available.
Visit website →Reunion Neuroscience (Private)
PrivateCompany went PRIVATE in 2023 — no longer publicly traded. Raised $133M Series A (MPM BioImpact, Novo Holdings). RE104 'luvesilocin' is a prodrug of 4-OH-DiPT — NOT a synthetic psilocybin analog or 4-F-MPMI. Phase 2 RECONNECT trial completed with positive results August 18, 2025: -23.0 vs -17.2 MADRS reduction (p=0.0094). FDA granted Breakthrough Therapy Designation February 23, 2026. Phase 3 initiation targeted 2026.
Visit website →Seelos Biosciences
Private⚠ DEFUNCT: SLS-002 Phase 2 FAILED primary endpoint September 2023. Delisted from Nasdaq October 16, 2024. Filed Chapter 11 bankruptcy November 15-16, 2024. Assets $0–$100K vs $10–50M liabilities. No ongoing clinical program.
Visit website →Ready to explore psychedelic therapy?
Browse our directory of 700+ verified ketamine and psychedelic therapy clinics across 49 states.